Bill SponsorBILLSPONSOR
Bill Sponsor
Politicians
Bills
House Bill 6930
116th Congress(2019-2020)
MADE in America Act of 2020
Introduced
Introduced
Introduced in House on May 19, 2020
Overview
Text
Introduced
May 19, 2020
Latest Action
May 19, 2020
Origin Chamber
House
Type
Bill
Bill
The primary form of legislative measure used to propose law. Depending on the chamber of origin, bills begin with a designation of either H.R. or S. Joint resolution is another form of legislative measure used to propose law.
Bill Number
6930
Congress
116
Policy Area
Health
Health
Primary focus of measure is science or practice of the diagnosis, treatment, and prevention of disease; health services administration and funding, including such programs as Medicare and Medicaid; health personnel and medical education; drug use and safety; health care coverage and insurance; health facilities. Measures concerning controlled substances and drug trafficking may fall under Crime and Law Enforcement policy area.
Sponsorship by Party
Republican
Buddy Carter
Georgia
Republican
Bruce Westerman
Arkansas
Republican
Rick Crawford
Arkansas
Democrat
Darren Soto
Florida
Republican
Jeff Van Drew
New Jersey
Democrat
Matt Cartwright
Pennsylvania
Republican
Tom Rice
South Carolina
Republican
Morgan Griffith
Virginia
Republican
David McKinley
West Virginia
House Votes (0)
Senate Votes (0)
No House votes have been held for this bill.
Summary

Manufacturing API, Drugs, and Excipients in America Act of 2020 or the MADE in America Act of 2020

This bill establishes a tax credit for taxpayers engaged in medical production activities in certain areas and contains other provisions related to pharmaceuticals.

An eligible taxpayer may claim a tax credit equal to 30% of qualified expenditures related to the production of pharmaceuticals, medical devices, or other related items in a designated qualified opportunity zone with a poverty rate higher than 30%.

In addition, the Food and Drug Administration shall continue a program to evaluate new drug manufacturing technologies included in an application for approval of a drug or biological product. The bill imposes various requirements on this program, including deadlines for evaluating such a technology.

Furthermore, the Department of Health and Human Services shall establish or expand programs to promote regulatory consistency and cooperation with drug regulatory authorities in other countries.

Text (1)
Introduced in House
May 19, 2020
Actions (2)
05/19/2020
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
05/19/2020
Introduced in House
Public Record
Record Updated
Jan 11, 2023 1:42:52 PM
Copyright © 2024 Civic Bits LLC
Privacy Policy
Terms of Service
What's New
About